טוען...
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications
Tamoxifen reduces recurrence risk among women treated for estrogen receptor-positive breast cancer. Its effectiveness partly depends on metabolic activation via cytochrome P450 2D6 (CYP2D6). Some medications compromise CYP2D6 activity and may lower plasma concentrations of active tamoxifen metabolit...
שמור ב:
| Main Authors: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2742564/ https://ncbi.nlm.nih.gov/pubmed/19690182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-09-0516 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|